Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TTK peptide vaccine in refractory breast cancer
NCT00678509Phase 2Terminated
- Sponsor
- The University of Tokyo
- Start
- May 2008
- Primary completion
- Mar 2009
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TTK-567 in breast cancer, sponsored by The University of Tokyo. Primary endpoints: Safety and tolerability at 2 months and Clinical response at 2 months. Started May 2008; status: terminated.
02
Drugs
TTK-567
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00678509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00678509.